DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
PF-03715455 is an investigational drug.
There have been 4 clinical trials for PF-03715455. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2015.
The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, and Lung Diseases. The leading clinical trial sponsors are Pfizer and [disabled in preview].
There are nine US patents protecting this investigational drug and one hundred and fifty-four international patents.
Recent Clinical Trials for PF-03715455
|An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease||Pfizer||Phase 2|
|An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma||Pfizer||Phase 2|
|Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers||Pfizer||Phase 1|
Top disease conditions for PF-03715455
Top clinical trial sponsors for PF-03715455
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|PF-03715455||Start Trial||Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors||ASTRAZENECA AB (Sodertalje, SE)||Start Trial|
|PF-03715455||Start Trial||Chemical compounds||AstraZeneca AB (Sodertalje, SE)||Start Trial|
|PF-03715455||Start Trial||P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD||Fulcrum Therapeutics, Inc. (Cambridge, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|